Background Campylobacter jejuni is the predominant antecedent infection in Guillain-Barré syndrome (GBS). Molecular mimicry and cross-reactive immune responses to C. jejuni lipo-oligosaccharides (LOS) precipitate the development of GBS, although this mechanism has not been established in patients from developing countries. We determined the carbohydrate mimicry between C. jejuni LOS and gangliosides, and the cross-reactive antibody response in patients with GBS in Bangladesh. Methodology Sera from 97 GBS patients, and 120 neurological and family controls were tested for antibody reactivity against LOS from C. jejuni isolates from GBS patients in Bangladesh (BD-07, BD-39, BD-10, BD-67 and BD-94) by enzyme-linked immunosorbent assay (ELISA). Cross-reactivity to LOS was determined by ELISA. The LOS outer core structures of C. jejuni strains associated with GBS/MFS were determined by mass spectrometry. Principle Findings IgG antibodies to LOS from C. jejuni BD-07, BD-39, BD-10, and BD-67 IgG antibodies were found in serum from 56%, 58%, 14% and 15% of GBS patients respectively, as compared to very low frequency (<3%) in controls (p<0.001). Monoclonal antibodies specific for GM1 and GD1a reacted strongly with LOS from the C. jejuni strains (BD-07 and BD-39). Mass spectrometry analysis confirmed the presence of GM1 and GD1a carbohydrate mimics in the LOS from C. jejuni BD-07 and BD-39. Both BD-10 and BD-67 express the same LOS outer core, which appears to be a novel structure displaying GA2 and GD3 mimicry. Up to 90–100% of serum reactivity to gangliosides in two patients (DK-07 and DK-39) was inhibited by 50 μg/ml of LOS from the autologous C. jejuni isolates. However, patient DK-07 developed an anti-GD1a immune response while patient DK-39 developed an anti-GM1 immune response. Conclusion Carbohydrate mimicry between C. jejuni LOS and gangliosides, and cross-reactive serum antibody precipitate the majority of GBS cases in Bangladesh.
References
[1]
Hughes RA, Cornblath DR (2005) Guillain-Barré syndrome. Lancet 366: 1653–1666.
[2]
Islam Z, Jacobs BC, Islam MB, Mohammad QD, Diorditsa S, et al. (2011) High incidence of Guillain-Barré syndromein children, Bangladesh. Emerg Infect Dis 17: 1317–1318.
[3]
Rees JH, Soudain SE, Gregson NA, Hughes RA (1995) Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 333: 1374–1379.
[4]
Jacobs BC, Rothbarth PH, van der Meché FG, Herbrink P, Schmitz PI, et al. (1998) The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 51: 110–1115.
[5]
Nachamkin I, Arzarte Barbosa P, Ung H, Lobato C, Gonzalez Rivera A, et al. (2007) Patterns of Guillain-Barré syndromein children: results from a Mexican population. Neurology 69: 1665–1671.
[6]
Islam Z, Jacobs BC, van Belkum A, Mohammad QD, Islam MB, et al. (2010) Axonal variant of Guillain-Barré syndromeassociated with Campylobacter infection in Bangladesh. Neurology 74: 581–587.
[7]
Ang CW, Jacobs BC, Laman JD (2004) The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 25: 61–66.
[8]
Yuki N (1997) Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome. J Infect Dis 176: S150–153.
[9]
Ang CW, Yuki N, Jacobs BC, Koga M, Van Doorn PA, et al. (1999) Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies. Neurology 53: 2122–2127.
[10]
Kusunoki S, Chiba A, Kanazawa I (1999) Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve 22: 1071–1074.
[11]
Aspinall GO, Lynch CM, Pang H, Shaver RT, Moran AP (1995) Chemical structures of the core region of Campylobacter jejuni O:3 lipopolysaccharide and an associated polysaccharide. Eur J Biochem 231: 570–578.
[12]
Godschalk PC, Kuijf ML, Li J, St Michael F, Ang CW, et al. (2007) Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain- Barré and Miller Fisher syndromes. Infect Immun 75: 1245–1254.
[13]
Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27: S21–24.
[14]
Islam Z, van Belkum A, Cody AJ, Tabor H, Jacobs BC, et al. (2009) Campylobacter jejuni HS:23 and Guillain-Barré syndrome, Bangladesh. Emerg Infect Dis 15: 1315–1317.
[15]
Penner JL, Hennessy JN, Congi RV (1983) Serotyping of Campylobacter jejuni and Campylobacter coli on the basis of thermostable antigens. Eur J Clin Microbiol Infect Dis 2: 378–383.
[16]
Jacobs BC, Hazenberg MP, van Doorn PA, Endtz HP, van der Meché FG (1997) Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. J Infect Dis 175: 729–733.
[17]
Kuijf ML, Godschalk PC, Gilbert M, Endtz HP, Tio-Gillen AP, et al. (2007) Origin of ganglioside complex antibodies in Guillain-Barré syndrome. J Neuroimmunol 188: 69–73.
[18]
Jacobs BC, Endtz HP, van der Meché FG, Hazenberg MP, de Klerk MA, et al. (1997) Humoral immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barré and Miller Fisher syndrome. J Neuroimmunol 79: 62–68.
[19]
Kuijf ML, Samsom JN, van Rijs W, Bax M, Huizinga R, et al. (2010) TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation. J Immunol185: 748–755.
[20]
Kuijf ML, van Doorn PA, Tio-Gillen AP, Geleijns K, Ang CW, et al. (2005) Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci 239: 37–44.
[21]
Li J, Koga M, Brochu D, Yuki N, Chan K, et al. (2005) Electrophoresis-assisted open-tubular liquid chromatography/mass spectrometry for the analysis of lipo-oligosaccharide expressed by Campylobacter jejuni. Electrophoresis 26: 3360–3368.
[22]
Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, et al. (1993) A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 178: 1771–1775.
[23]
Yuki N, Kuwabara S (2007) Axonal Guillain-Barré syndrome: carbohydrate mimicry and pathophysiology. J Peripher Nerv Syst 12: 238–249.
[24]
Jacobs BC, van Doorn PA, Schmitz PI, Tio-Gillen AP, Herbrink P, et al.. (1996) Campylobacter jejuni infections and anti-GM1 antibodies in guillain-barré syndrome. Ann Neurol 40; 181–187.
[25]
Salloway S, Mermel LA, Seamans M, Aspinall GO, Nam Shin JE, et al. (1996) Miller-Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3. Infect Immun 64: 2945–2949.
[26]
Ang CW, Laman JD, Willison HJ, Wagner ER, Endtz HP, et al. (2002) Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients. Infect Immun 70: 1202–1208.
[27]
Xiang SL, Zhong M, Cai FC, Deng B, Zhang XP (2006) The sialic acid residue is a crucial component of C. jejuni lipooligosaccharide ganglioside mimicry in the induction Guillain-Barré syndrome. J Neuroimmunol 174: 126–132.
[28]
Kaida KD, Morita MK, Kanzaki M, Kamakura K, Motoyoshi K, et al. (2004) Ganglioside complexes as new target antigens in Guillain-Barré syndrome. Ann Neurol 56: 567–571.
[29]
Kaida KI, Kanzaki M, Morita D, Kamakura K, Motoyoshi K, et al.. (2006) Anti-ganglioside complex antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psych 10.1136/jnnp; 087940.
[30]
Kaida K, Ariga T, Yu RK (2009) Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders–a review. Glycobiology 197: 676–692.
[31]
Koga M, Gilbert M, Takahashi M, Li J, Koike S, et al. (2006) Comprehensive analysis of bacterial risk factors for the development of Guillain-Barré syndrome after Campylobacter jejuni enteritis. J Infect Dis 193: 547–555.
[32]
Nachamkin I, Liu J, Li M, Ung H, Moran AP, et al. (2002) Campylobacter jejuni from patients with Guillain– Barré syndrome preferentially expresses a GD(1a)-like epitope. Infect Immunol 70: 5299–5303.
[33]
Gilbert M, Karwaski MF, Bernatchez S, Young NM, Taboada E, et al. (2002) The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J Biol Chem 277: 327–337.
[34]
Godschalk PC, Heikema Astrid P, Michel Gilbert, Tomoko Komagamine, Ang CW, et al. (2004) The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barré syndrome; J Clin Invest. 114: 1659–1665.
[35]
Koga M, Takahashi M, Masuda M, Hirata K, Yuki N (2005) Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome. Neurology 65: 1376–1381.
[36]
van Belkum A, van den Braak, Godschalk PC, Ang CW, Jacobs BC, et al. (2001) A Campylobacter jejuni gene associated with immunemediated neuropathy. Nat Med 7: 752–753.
[37]
Islam Z, van Belkum A, Wagenaar JA, Cody AJ, de Boer AG, et al. (2009) Comparative genotyping of Campylobacter jejuni strains from patients with Guillain-Barré syndrome in Bangladesh. PLoS One 4: e7257.
